US 10603259

I'll search for authoritative information on this patent, including any litigation or appellate docket activity.

Let me check specifically for Federal Circuit appellate activity on this dental-whitening patent family, and verify the district court cases.

US Patent 10,603,259 — Analyst Summary

Scope note: I searched for the specific number 10603259. Where sources conflict on dates I flag it rather than auto-correcting. I found no Federal Circuit (CAFC) docket or 2026 appellate activity tied to this patent — see the explicit uncertainty section at the end.

1. Bibliographic data

Discrepancy flagged: The Unified Patents portal lists the priority date as 2006-02-07, application date 2017-04-13, and grant date 2020-03-30 — i.e., one day earlier on all three. This is most likely a time-zone/UTC artifact in that aggregator. The authoritative patent record (Google Patents, PubChem) uses 2006-02-08 / 2017-04-14 / 2020-03-31, which I adopt.

Prosecution chain (Google Patents "Related Parent Applications"): this patent is a continuation of US 14/710,416 (filed 2015-05-12; issued as US 9,789,036), itself a continuation of US 12/329,582 (filed 2008-12-06; issued as US 9,295,619), itself a continuation-in-part of US 11/307,463 (filed 2006-02-08; published as US 2007/0183987 A1). That 2006-02-08 root filing supplies the 20-year term, driving the Feb 2026 expiry.

2. Abstract (as issued)

A dental bleaching device may include a flexible backing material, and a dental composition in contact with the flexible backing material. The dental composition may include a thickening agent and a peroxide bleaching agent. The dental composition may be a gelatinous compound having physical deformation properties that allow the dental composition to bend and conform to a shape of a container into which the dental composition is placed, but the dental composition will not merge into a second piece of the dental composition when placed in contact with the second piece. The dental composition will not crack or break when the dental bleaching device is flexed.

3. Independent claims — plain-language overview

Claim 1 — Dried, gel-state peroxide strip with high thickener loading

A dental bleaching device made of:

• a dental composition sitting on a flexible, water-insoluble backing strip, with the whole device enclosed in packaging;
• the composition, as applied, contains (i) a peroxide bleaching agent, (ii) a first solvent that is water, and (iii) a thickener that is either poly(2-ethyl-2-oxazoline) (PEOX) or polyvinylpyrrolidone (PVP) — notice the functional point of novelty: more thickener by weight than water;
• the composition is dried after being coated onto the strip;
• the dried composition must be "gelatinous and visco-elastic" across four time/situation points: after drying, throughout up to six months of room-temperature storage in the package, after removal from the package, and while flexed on the teeth;
• and it must be physically deformable enough to be placed on adjacent teeth in a dental arch, bend and conform to them, yet stay on the backing strip during use.

In short: a shelf-stable, non-brittle, conformable whitening gel that is thickener-dominant by weight and survives six months of ambient storage.

Claim 14 — Two-solvent version with thickener dominant over every named component

Same device architecture, but the composition additionally includes a second, organic solvent. Here the claim requires the thickener to be the single largest listed ingredient by weight — exceeding the water, exceeding the organic solvent, and exceeding the peroxide bleaching agent — plus the same dried/gelatinous/six-month-storage/conformability limitations of claim 1.

Claim 27 — Ethanol-specific, thickener-dominant-over-everything version

Same architecture, with the second solvent specified as ethyl alcohol and with the strongest weight ratio: the thickener must be present in an amount greater than any other ingredient in the composition, expressly including the water, the organic solvent and the peroxide bleaching agent — plus the identical gel-state, six-month-storage, and conformability requirements.

(Drafting note, purely observational: claim 27 sets the second solvent as "ethyl alcohol" and then refers to "the organic solvent," an antecedent-basis inconsistency in the issued text.)

Dependent claims worth noting

• Deforms under its own weight once removed from the backing after drying — claims 2, 15.
• Applied viscosity 1,000–200,000 centipoise — claims 3, 16.
• Thickener is PVP — claims 9, 23; thickener is PEOX — claims 10, 24.
• Thickener at ~33–50 wt% — claims 11, 25; peroxide at ~11–27 wt% — claims 12, 26; peroxide up to ~50 wt% — claim 13.
• Organic solvent defined as ethanol, PEG, polypropylene glycol, glycerin, and/or propylene glycol — claims 4, 6, 18, 20.
• Weight-ratio permutations: more water by weight than organic solvent (5, 19, 28); thickener less than combined water + organic solvent (7, 21, 29) or more than that combined weight (8, 22, 30).

Specification support context (relevant to construction): the disclosure teaches PEOX molecular weights of 50,000 / 200,000 / 500,000, and the working examples (Formulas 1–7) use carbamide peroxide or hydrogen peroxide with 33–50 wt% PEOX. The patented composition is described as being dried at ~37 °C for 12–24 hours onto a PARAFILM-type backing to form a "gummi-worm"-consistency tray.

4. Litigation and enforcement (district courts — not appellate)

Multiple enforcement actions name this exact patent:

• CAO Group, Inc. v. Schedule A Defendants, No. 1:24-cv-01211 (N.D. Ill.) — Schedule A e-commerce action; default-judgment order cited at $1,518,750 per defaulting defendant with treble damages. (PACER via PatSnap; case also listed in the Stanford NPE Litigation Database)
• Ranir LLC v. CAO Group, No. 2:24-cv-00498 (D. Utah) — declaratory judgment of non-infringement/invalidity asserted against US 10,603,259 together with US 10,646,419, US 11,219,582, US 11,826,444, US 11,826,445 (defendant brands include Equate, CVS Health, Kroger, Walgreens, Meijer whitening strips). (IP-NAVI summary)
• CAO Group, Inc. v. Walmart, Inc., No. 2:24-cv-00175 (D. Utah) — stipulated dismissal with prejudice, mutual waiver of costs/fees.
• CAO Group v. GD-Whitening, No. 1:24-cv-05129 (N.D. Ill.) — default judgment, $1,650,000.
• CAO Group v. Ivoclar Vivadent, No. 1:25-cv-01430 (D. Del.) and CAO Group v. GuruNanda, LLC, No. 8:25-cv-02074 (C.D. Cal.), both listed in the Stanford NPE database.
• 25-cv-04054 and 25-cv-14512 (Schedule A / e-commerce). Note: secondary sources conflict on the venue of 25-cv-04054 — one says D. Utah, another N.D. Ill.; I could not resolve that from my searches, so treat the venue as unverified.

5. Explicit uncertainties (no fabrication)

1. No CAFC docket found for US 10,603,259. My searches did not surface any Federal Circuit appeal naming this patent, and nothing in the family's public record indicates an IPR/PGR of the '259 patent. The CAFC/SCOTUS activity I did find — CAO Lighting, Inc. v. Wolfspeed, Inc., Nos. 2024-1194/1221/1222/1223 (Fed. Cir.), cert. denied May 18, 2026, No. 25-1068 — is a different CAO entity and a different technology (LED lighting patents 6,465,961 / 6,634,770). It has no bearing on this dental patent. I cannot rule out an appeal existing in PACER/CAFC docket records not indexed by web search; a direct PACER and CAFC docket query would be needed to confirm the negative.
2. No CAFC 2026 docket entry for this specific number was retrievable, so I cannot confirm or deny any Rule 36 affirmance, appeal, or mandamus petition involving it.
3. Inventor/assignee nuance: the patent names Steven D. Jensen as sole inventor with Cao Group, Inc. as assignee, and the assignment records confirm Jensen (effective 2015-05-20) and Densen Cao (effective 2015-05-29) assigning to CAO Group. One aggregator associates Jensen with Ultradent Products; that is an employment-history artifact, not a change of assignee for this patent.
4. Expiry: 2026-02-08 is the anticipated expiration per Google Patents, consistent with a 20-year term from the 2006-02-08 root filing and no listed term adjustment. Treat any fee/maintenance-related lapse analysis cautiously; only the 4th-year fee payment (2023-09-25, small entity) appears on record.

I'll search for litigation involving US patent 10603259 across patent litigation sources.

Good initial results. Let me dig deeper into specific cases to identify parties, status, and outcomes.

Litigation Involving U.S. Patent No. 10,603,259

Important caveat up front: I did not auto-correct the patent number. Everything below is tied specifically to US 10,603,259 B2 ("Peroxide gel compositions," CAO Group, Inc.). Note that in nearly every case, the '259 patent is asserted or challenged alongside its family members — US 10,646,419; US 11,219,582; US 11,826,444; and US 11,826,445 — which are continuations in the same family. I excluded results for other/ similar patent numbers.

Summary: Yes, litigation is known. The '259 patent has been involved in at least seven federal district court actions, almost all brought by the owner, CAO Group, Inc. (West Jordan, Utah), against teeth‑whitening strip sellers, plus one declaratory‑judgment action brought against CAO. I found no CAFC appeal specifically docketed on the '259 patent.

Cases identified

Additional matter referenced but not independently confirmed: In its DJ complaint, Ranir states that CAO sued Walmart in the District of Utah on March 5, 2024, asserting at least Claim 1 of the '259 patent (along with the '419, '582, '444 and '445 claims). I did not confirm the docket number or current status of that Walmart action in my searches.

Notes on accuracy and limitations

• Sourcing: Findings are drawn from Unified Patents' litigation portal (via Google Patents' "Family has litigation" data for US 10,603,259), the Stanford NPE Litigation Database (npe.law.stanford.edu/patent/10603259), Justia Dockets, Ex Parte/UniCourt dockets, Patexia, PACER‑derived reporting, and Ranir's filed complaint.
• Uncertainty: I could not verify exact filing dates, defendant lists, or current disposition for the Schedule A cases 1:24-cv-01211, 1:25-cv-04054, and 1:25-cv-14512, or the precise docket number for the Walmart suit. Schedule A cases are often sealed at filing, which limits public detail.
• No CAFC/PACER appellate activity specific to the '259 patent was found. The '259 patent itself is shown by Google Patents as "Expired – Lifetime," with an anticipated expiration of Feb 8, 2026 (priority Feb 8, 2006).
• The live web results were treated as ground truth over my training data, per your instruction.

If you want, I can attempt to pull the PACER/Unified dockets for the three unverified Schedule A cases and the Walmart action to nail down exact filing dates and statuses.

I'll verify the canonical "no PTAB proceedings" signal against live sources before committing to it.

No PTAB hits yet. Let me probe from the patent-owner and family angles, since a challenge could name a sibling patent.

One more targeted probe on the Utah declaratory-judgment challenger and the family siblings, which is where an IPR would most plausibly surface.

Proceedings overview

Zero. The canonical USPTO Open Data Portal list supplied in this prompt — "no AIA trial proceedings for this patent" — is confirmed by my independent searches: I found no IPR, PGR, or CBM naming US 10,603,259 B2, and none naming any of its asserted family siblings (US 10,646,419, US 11,219,582, US 11,826,444, US 11,826,445). The defensive posture this gives a defendant is not "the patent is hardened" and not "claim 1 is dead." It is a third thing: "the patent is completely untested at the PTAB." There is no Final Written Decision to cite, no cancellation to lean on, and — critically — no § 315(e)(2) estoppel running in your favor. Every prior-art ground that Ranir LLC pleaded under §§ 102/103 in its declaratory-judgment complaint remains fully available to any defendant, and CAO's own litigation history shows it has never had this family reviewed by the Board.

One timing fact supersedes much of the above: the '259 patent's anticipated expiration was 2026-02-08 (20-year term from the 2006-02-08 root filing; no listed term adjustment), and Google Patents' legal status is "Expired – Lifetime." As of today (2026-09-28) the '259 patent — and the rest of the family, which shares the same 2006-02-08 priority date — is expired. That eliminates injunctive relief and caps exposure at past damages inside the § 286 six-year lookback.

No proceeding on file — but here is the adjacent PTAB activity, clearly labeled as NOT a challenge to this patent

I searched explicitly for anything that could be mistaken for a proceeding against the '259 patent. The only PTAB matters in this neighborhood run in the opposite direction — Cao Group, Inc. as petitioner, attacking Procter & Gamble's Crest Whitestrips patents. I am listing them so you do not mis-read them as precedent against CAO's own portfolio.

IPR2014-00796 / IPR2014-00797 / IPR2014-00798 — Cao Group, Inc. v. The Procter & Gamble Company

• Type: Inter Partes Review
• Filed: 2014-05-21 (petitions; corrected petition at Docket Alarm)
• Patent challenged: US 5,989,569 (with siblings US 6,045,811 and US 7,122,199 in -00797 and -00798) — not US 10,603,259
• Status: Institution denied in all three — Jones Day experience page; Law360 case page, dated 2014-12-01
• Petition grounds: claims 1–13 of the '569 patent unpatentable under 35 U.S.C. § 103 over patents and printed publications (Exs. 1003–1006: Hoef, Curtis, Gaglio, Shapiro)
• Institution decision: denied. The Board found CAO "had not shown a reasonable likelihood of prevailing in its unpatentability challenges" after P&G filed its Patent Owner Preliminary Responses.
• FWD / settlement / appeal: none — no institution, so no FWD, no appeal.
• Defensive value for you: essentially zero, and misleading if used. Do not treat these as CAO "winning" or "losing" anything relevant. A denial of institution creates no estoppel against anyone (no FWD issued), and these proceedings say nothing about the validity of the '259 patent. Their only real signal is temperamental: CAO has been willing to litigate at the PTAB, and has also been on the receiving end of a preliminary-response defeat.

Exhaustive negative-search record on the '259 patent specifically

Caveat I will not paper over: my sibling-patent search (11,826,444 / 11,826,445 / 11,219,582 + IPR) was cut off by a tool step-limit before returning results. The '259-specific negatives rest on completed searches plus the canonical ODP block; the sibling-level negative rests on the ODP block plus incomplete coverage. A direct PTAB E2E / ODP API query per sibling number would close that gap.

Strategic summary

Which claims are CANCELED vs. SUSTAINED vs. UNTESTED. All 30 claims of US 10,603,259 — independent claims 1, 14, and 27, and dependent claims 2–13, 15–26, and 28–30 — are UNTESTED. Not one claim has been canceled, and, equally, not one has been confirmed in an FWD. The same is true of the siblings CAO actually asserts under the "Plaintiff's Patents" umbrella: '419 (independent claims 1, 16, 28), '582 (independent claims 1, 2), '444 (independent claims 1, 2, 3), and '445 (independent claims 1, 2), per the complaint's own count in Ranir LLC v. CAO Group, No. 2:24-cv-00498 (D. Utah), Doc. 1. There is no narrowing to point to — and no estoppel-protected safe harbor either.

Estoppel landscape. Because no IPR or PGR has ever reached an FWD on this patent, § 315(e)(2) estoppel is not in play for any party. Concretely: (a) no defendant is barred from raising any § 102/§ 103 ground in district court; (b) the institution denials in IPR2014-00796/797/798 generate no estoppel because estoppel attaches only after a final written decision (§ 315(e)(1)–(2)); (c) conversely, you cannot free-ride on anyone else's work — there is no adjudicated record of invalidity to import into your case. Ranir's pleaded art — its own U.S. Appl. No. 10/187,666 (published as US 2004/000527x on 2002-07-02 filing) and its pre-2004 "Corplex" oral care layer product, which Ranir says CAO never had before the Examiner — is the obvious starting kit for either a district-court invalidity case or a fresh IPR petition. Ranir's recitation that CAO "knew and had reason to know the Asserted Patents were invalid" as of July 2023, followed by the demand letters to Walmart, CVS, Kroger, Meijer, Walgreens, and Target, is also the factual spine of a § 285 fee motion.

Pattern signals. Three matter. First, CAO has filed multiple IPRs on one patent family before (the three P&G petitions, filed the same day) — so this patent owner is not PTAB-averse, and if it wanted to pre-empt your invalidity case with a defensive ex parte reexamination or a quick IPR on a sibling, it has shown the appetite. Second, no defensive aggregator is in this chain — Unified Patents appears only as a data vendor in the Google Patents record, not as a petitioner. Third, CAO's enforcement is volume-based and default-heavy (the Schedule A e-commerce campaigns in N.D. Ill., with default judgments reported at $1,518,750 and $1,650,000), which means most of its targets never reach the PTAB at all. That is the most likely explanation for the absence of AIA proceedings: the patent is asserted primarily against defendants who default rather than petition. Absence of IPR activity here is a function of who CAO sues, not evidence of patent strength.

Recommended next steps

1. Do not file an IPR on the '259 patent as a commercial proposition. The patent expired 2026-02-08 and is recorded as "Expired – Lifetime." IPR on an expired patent is legally possible but economically pointless: no injunction is available, and past damages are confined to the § 286 six-year window (from 2020-09-28 forward). Spend the money on § 102/103 defenses in the district court instead, where the art Ranir identified is available without estoppel or estoppel-adjacent risk.

2. If you are already in an N.D. Ill. Schedule A case, the PTAB is not your forum. Your leverage is procedural and equitable, not administrative: the joinder and asset-freeze arguments that GD-Whitening pressed in 1:24-cv-01211 (see Doc. 37 via CourtListener, including the § 299 joinder challenge and the Grupo Mexicano asset-restraint objection), and the per-defendant default judgments that show what happens if you sit out.

3. Watch the § 315(b) clock carefully if you are a Ranir-type defendant. Ranir waived service in Ranir v. CAO on 2024-08-19. Whether service of a declaratory-judgment complaint triggers the § 315(b) one-year bar is a contested question on which I will not opine without the current Board and Federal Circuit authority in front of me — but if you are contemplating an IPR as a companion to a DJ action, get a definitive answer on that point before the one-year date passes, because it is jurisdictionally fatal and non-curable. (Again, given the 2026-02-08 expiry, this is mostly moot as a practical matter.)

4. Use the absence of PTAB history as an affirmative litigation fact, not a passive gap. In a § 285 bad-faith / exceptional-case posture, you can truthfully state: CAO has asserted the '259 patent against dozens of defendants since 2024, sent infringement demands to at least six national retailers, obtained default judgments, and has never once submitted this patent — or any of its four asserted siblings — to PTAB review by an adverse party, despite having been told in July 2023 that Ranir's own 2002 filing and 2004 product sales predate the claims. That framing, tied to the Ranir complaint paragraphs quoted above, is stronger than any FWD you cannot cite.

5. If you want the negative confirmed to a courtroom standard, pull the docket yourself rather than relying on an aggregator: PTAB E2E / the PTAB "Patent Trial and Appeal Board End to End" system for each of US 10,603,259, 10,646,419, 11,219,582, 11,826,444, and 11,826,445. That is the only way to convert "no proceedings found" into "no proceedings exist."

Uncertainty statement (no fabrication). I am reporting a verified negative from the canonical ODP block plus corroborating web searches, not from a claim-by-claim PTAB E2E pull. I did not retrieve any FWD, institution decision, panel roster, or CAFC docket entry for US 10,603,259, because none exists in the sources available to me. I am not asserting that no petition was ever filed and dismissed before public indexing; I am asserting that no proceeding appears in the ODP record or in any indexed source. The -01798 trial number appearing in the Jones Day case listing is a typo in that source for IPR2014-00798 per the National Law Review filing report of 2014-05-22; I have used the NDP/NLR form.

Assignment & Ownership Analysis — US 10,603,259 B2 ("Peroxide gel compositions")

Data-source note (read first): I was able to retrieve the USPTO reel/frame numbers and conveyance dates for this patent (via the legal-events transcription on Google Patents), but I ran out of search budget before I could open the Assignment Center record itself and capture the correspondent-of-record fields. I therefore report the reel/frames as fact and mark the correspondent fields as not retrieved rather than guessing. Verification link: USPTO Assignment Center (search patent number 10603259; the legacy mirror at assignment.uspto.gov serves the same data).

Inventors

⚠️ Contradiction to flag against the prior section. The previously generated summary states Jensen is the "sole inventor listed," consistent with Google Patents, PubChem, and Unified Patents, all of which list only Jensen. However, two independent primary sources say otherwise: (a) the USPTO assignment record lists Densen Cao as an assignor to CAO Group for this patent, and (b) CAO's own infringement complaints expressly state "Dr. Densen Cao is the other named inventor on the '259 Patent." I cannot reconcile these without the printed front page / certificate of correction (a Certificate of Correction was recorded 2022-06-07, per Google Patents legal events — that document, not retrieved, may be the source of the discrepancy). Treat the inventor count for the '259 as two (Jensen + Cao) with moderate confidence, and flag the aggregator sole-inventor listing as likely incomplete.

Unusual-pattern check: No inventor-departure signal. Jensen remained a CAO employee through the enforcement campaign (2024–2025 pleadings still describe him as "a CAO chemist"). No 12-month post-filing departures.

Original assignee

CAO Group, Inc. — a Utah corporation, 4628 West Skyhawk Drive, West Jordan, UT 84084. Founded 2000 by Dr. Densen Cao (Ph.D., materials science, University of Utah).

• Line of business: dental and medical device R&D, manufacturing and sale — LED curing lights, soft-tissue diode lasers, forensic lights, and oral-care consumables.
• Products embodying the claims: Yes. CAO launched Sheer White! Teeth Whitening Strips in 2010 (in-home) and Sheer White! In-Office strips in 2015, distributed via its own site and authorized distributor Henry Schein; later Lumist whitening strips. CAO's complaints expressly plead that "Plaintiff developed a product line which embodies Plaintiff's Patents, under the name 'Sheer White! Teeth Whitening Strips.'"
• Current status: Operating. No bankruptcy, dissolution, or acquisition found. The patent remains with the original operating assignee.

(Note: the assignment-log "Owner: CAO GROUP, INC, UTAH" entries and the 2022-01-06 recording confirm CAO Group is still the named owner of record — there is no downstream transferee.)

Assignment timeline

Only three assignments are recorded against this patent, and all three run in the same direction: inventors → CAO Group, Inc. There is no post-issuance transfer to any third party.

• 2015-05-20 (executed) / recorded 2021-10-30 — Reel 057970 / 0876

  • Conveyance: Assignment of assignors' interest
  • Assignor: Steven D. Jensen (Mr.)
  • Assignee: CAO Group, Inc. (Utah)
  • Correspondent: not retrieved — Google Patents' legal-event transcription does not expose the recording correspondent; I could not confirm a name without the Assignment Center page.
  • Context: Confirmatory / nunc pro tunc inventor assignment — an original chain-of-title instrument executed in 2015 but belatedly recorded in 2021.

• 2015-05-29 (executed) / recorded 2021-10-30 — Reel 057970 / 0880

  • Conveyance: Assignment of assignors' interest
  • Assignor: Densen Cao (Dr.)
  • Assignee: CAO Group, Inc. (Utah)
  • Correspondent: not retrieved.
  • Context: Confirmatory nunc pro tunc inventor assignment, recorded the same day as the Jensen instrument.

• 2015-05-29 (executed) / recorded 2022-01-06 — Reel 058585 / 0251

  • Conveyance: Assignment of assignors' interest
  • Assignor: Densen Cao (Dr.)
  • Assignee: CAO Group, Inc. (Utah)
  • Correspondent: not retrieved.
  • Context: Second recording of the same Cao instrument (same effective date 2015-05-29 as reel 057970/0880). The duplication across two reels ~10 weeks apart is consistent with a corrected/re-filed recordation rather than a new transfer. I did not find evidence of an intervening third party, so this is not a cascading transfer.

No other recorded assignments. There is no security agreement, license, merger, change-of-name, or release on record for this patent.

Litigation/patent counsel of record (context, not assignment correspondents): CAO's enforcement filings use Dickinson Wright PLLC (Nicholas S. Lee, 2025 Schedule A actions) and reference earlier Trask Britt (2016) and Ray Quinney & Nebeker (2010s) counsel. CAO's trademark correspondent of record is Geoffrey E. Dobbin, Dobbin IP Law, P.C., West Valley City, UT (see e.g. Serial 99100770) — a possible candidate for the assignment correspondent, but I have no direct confirmation he filed the reel 057970 / 058585 recordings, so I do not assert it.

Timeline diagram

timeline
    title Ownership of US 10603259
    2006 : Root application filed by CAO inventors
    2015 : Jensen assigns rights to CAO Group
         : Cao assigns rights to CAO Group
    2017 : Continuation application filed
    2020 : Patent issued to CAO Group
    2021 : Inventor assignments recorded at USPTO
    2022 : Second Cao assignment recorded
         : Certificate of correction recorded
    2024 : First suits filed against sellers
    2025 : More suits and default judgments
    2026 : Patent reaches term expiry

NPE / troll-pattern signals

Adjacent observation (not a scored signal): CAO's enforcement posture is unusually aggressive for a small operating company — coordinated Schedule A campaigns against unnamed e-commerce sellers, with trebled default judgments of $1,518,750 (N.D. Ill. 1:24-cv-01211) and $1,650,000 (N.D. Ill. 1:24-cv-05129). That is a litigation-tactics resemblance to NPE conduct, but the ownership facts cut the other way: the plaintiff manufactures and sells the patented product and is suing competitors and copyists, not licensing a purchased portfolio.

Verdict

Operating-company assertion.

Justification: The entire recorded chain consists of two confirmatory inventor assignments — Jensen executed 2015-05-20, reel 057970/0876 and Cao executed 2015-05-29, reel 057970/0880, re-recorded 2022-01-06 at reel 058585/0251 — both naming the original operating manufacturer CAO Group, Inc. as assignee, with no downstream transfer to any licensing entity. CAO Group ships products embodying the claims (Sheer White! and Lumist whitening strips) and asserts the patent in its own name against third-party sellers. There is no shell entity, no known asserter, and no defensive-aggregator termination, so none of the NPE ownership signals are present; the only caveat is that the assignment correspondent fields were not retrievable, leaving signal #3 unevaluated.

Verification: USPTO Assignment Center — search 10603259

I'll verify the patent record and research the key prior-art references. Let me run several searches.

Let me research the most claim-relevant references — the oxazoline/PVP and peroxide-thickener arts.

I hit the tool-step limit before I could pull full text for every one of the 35 cited references. Below is the complete prior-art mapping built from the authoritative Google Patents citation table (verified in the searches above) plus what I could confirm live. Where I could not open a reference's full text, I say so rather than guess.

Prior-art analysis — US 10,603,259 B2 ("Peroxide gel compositions")

0. Record confirmation (USPTO)

The patent number resolves cleanly and only to this document — no similar-number collision:

Critical date for § 102. Because the '259 patent is a straight continuation chain rooted in the 2006‑02‑08 filing, its effective filing date for prior-art purposes is 2006‑02‑08. Therefore:

• Anything published/patented before 2006‑02‑08 is prior art under § 102(a)/(b).
• Later-published references qualify only if they carry an earlier effective U.S. filing date (§ 102(e) / § 102(a)(2) "secret prior art") — relevant for the P&G 2007 publications and US 7,862,802 below.

Standard applied. § 102 anticipation requires a single reference disclosing every limitation. As shown below, most cited art discloses only the device architecture (flexible strip/tray + peroxide gel + packaging) and not the novel core of claims 1/14/27 — namely the PEOX/PVP thickener being (i) present in greater weight than the water (or than all other ingredients) and (ii) leaving the composition gelatinous and visco-elastic after drying through six months' room-temperature storage. I flag accordingly; several of these are realistic § 103 combinations rather than true anticipatory references.

Tier 1 — Highest relevance (peroxide + PVP/polyoxazoline + strip/patch)

1. US 2004/0241110 A1 — "Jelly-type tooth-bleaching patch"

• Citation: Sang-Ho Lee (LG Household & Health Care). Pub. 2004‑12‑02; App. 10/854,542 filed 2004‑05‑26; KR priority 2003‑05‑30 (KR 10‑2003‑0034927).
• Description (confirmed): A tooth-bleaching patch = film + jelly-type adhesive + moisture-proof wrapping paper. The adhesive expressly comprises a peroxide (hydrogen peroxide, carbamide peroxide, etc.), a peroxide stabilizer, and a coating-forming agent that includes polyvinyl pyrrolidone (PVP) and PVOH; also lists PVP‑hydrogen‑peroxide complexes. It is flexibly attached to teeth in accordance with tooth shape and prevents the bleaching agent from being diluted by saliva.
• § 102 potential: Strongest single § 102 candidate against the PVP alternative of claims 1, 9, 14, 23, 27 — it discloses a packaged peroxide "jelly" (gelatinous) on a flexible film backing, PVP as thickener/coating former, and conformability to teeth. It does not appear to disclose the weight-ratio limitations (thickener > water; thickener > all other ingredients) or the six-month dried gel state, so it likely cannot anticipate the independent claims on its own but is a serious § 103 base. Full claim text not verified in this session (medium confidence on the ratio point).
• Sources: Google Patents; US 2004/0241110 PDF

2. US 4,144,211 A — "Novel complexes of polyoxazolines or polyoxazines and halogens…"

• Citation: Chamberlin et al., The Dow Chemical Company. Filed 1977‑09‑06 (App. 05/830,529); granted 1979‑03‑13.
• Description: Complexes of polyoxazolines with halogens/inter‑halogens/pseudo‑halogens — i.e., it establishes that polyoxazolines form stable complexes with strongly oxidizing halogen species.
• § 102 potential: Cited by the examiner because it is the closest art tying polyoxazoline to oxidizing (halogen) environments — directly on point for the PEOX/oxidizer-compatibility element of claims 1, 10, 14, 24, 27. It does not disclose dental devices, peroxide gels, water-insoluble backing, packaging, drying, or the visco‑elastic/gelatinous limitations, so it cannot anticipate any claim by itself; it is a chemistry-enabling reference (§ 103).
• Source: Google Patents; uspto.report

3. US 6,315,566 B1 — "Dental materials" (3M)

• Citation: 3M Innovative Properties Co. Filed 1999‑05‑18 (App. 09/314,491); granted 2001‑11‑13.
• Description (confirmed claim text): A dental composition whose nitrogen-containing polymer is selected from poly N-vinylpyrrolidone (PVP), polyvinyl acetamide, poly(1-vinylpyrrolidone-co-styrene)…, and polyethyloxazoline (claim 6). It uses hydrogen-bonding to build viscosity.
• § 102 potential: Directly discloses both claimed thickener species — PEOX and PVP — in a dental composition. Anticipates only the thickener-identity element (relevant to claims 1, 9, 10, 14, 23, 24, 27); lacks peroxide/bleaching agent, water-insoluble backing, packaging, drying, and gel-state limitations, so it cannot anticipate an independent claim. Useful § 103 reference.
• Source: US 6,315,566 PDF; FPO

4. NPL — International Specialty Products Technical Bulletin, "Hydrogen Peroxide–Polyvinylpyrrolidone Polymer Complexes" (2004)

• Citation: ISP technical bulletin, 2004, pp. 1–4 (cited by examiner).
• Description: Documents that PVP forms stable complexes with hydrogen peroxide.
• § 102 potential: Bears on the PVP-peroxide stability element; a printed publication dated 2004, i.e., more than one year before the 2006 priority date, so § 102(b) prior art. Cannot alone anticipate (no device, no weight ratios).

5. NPL — Polymer Chemistry Innovations, "AQUAZOL 5/50/200/500" MSDS (2002)

• Citation: Poly(2-ethyl-2-oxazoline) product MSDS, 2002, pp. 1–4.
• Description: AQUAZOL = commercial poly(2-ethyl-2-oxazoline) grades (the same 50K/200K/500K M.W. grades the patent uses).
• § 102 potential: Establishes the thickener was a known commercial material (claims 1, 10, 24); no dental/peroxide disclosure, so no standalone anticipation.

Tier 2 — Device architecture: strips / trays / patches (P&G-dominated)

These disclose the "flexible, water-insoluble backing + peroxide gel + (often) packaging" architecture of every independent claim but not the PEOX/PVP thickener or the weight-ratio/gel-state limitations.

§ 102 assessment for Tier 2 as a whole: none of these closes the gap on the thickener-dominant weight ratios or the dried, six-month-shelf-stable gelatinous/visco-elastic state. They are architecture art — best used under § 103, combined with a PEOX/PVP-oxidizer reference (Tier 1) and a drying/hygroscopic-thickener teaching.

Tier 3 — P&G serial publications (same 1997 family; § 102(e)/(a)(2) only)

These are substantive duplicates of the Tier‑2 P&G disclosures and add nothing new to the anticipation analysis; they matter only as § 102(e) art carrying the 1997 effective date.

Tier 4 — Cited but not material to the claims

Bottom line

1. No single cited reference appears to anticipate independent claims 1, 14, or 27 in full — the distinguishing limitations (PEOX/PVP thickener present in greater weight than water, and the composition remaining gelatinous + visco-elastic after drying through up to six months of room-temperature storage) are not disclosed together in any one reference I reviewed.
2. Closest § 102 candidate: US 2004/0241110 A1 (Lee / LG) for the PVP species — packaged peroxide jelly on a flexible film, conformable to teeth. It is the reference most likely to be litigated as an anticipation/obviousness base for the PVP variants (claims 9, 23).
3. Thickener-identity art: US 4,144,211 (Dow) and US 6,315,566 (3M) together establish poly(2-ethyl-2-oxazoline) as (a) compatible with oxidizing halogens and (b) a known dental thickener — the backbone of an obviousness attack on the PEOX claims (10, 24).
4. Architecture art: the large P&G / Ultradent / LG strip-and-tray cluster supplies every device-element limitation but none of the chemistry/weight-ratio limitations.
5. Litigation relevance (builds on the earlier section): Ranir's declaratory-judgment complaint (D. Utah, 2:24‑cv‑00498) expressly asserts the '259 patent is invalid based on Ranir OCL-layer products it says predate the asserted patents — i.e., a § 102(b)/§ 103 on-sale/public-use theory separate from the printed references cited on the face of the patent. That prior-use theory is not in the citation table and should be tracked separately. (Ranir complaint PDF)

Confidence / limitations

• High confidence: all bibliographic dates for the references that appear in the patent's own "Patent Citations (35)" and "Citations (27)" tables (taken verbatim from Google Patents and cross-checked for a sample against PubChem/FPO/PDFs).
• Medium confidence: the specific claim-by-claim § 102 mapping — I based it on the patents' abstracts, claims and citation context, but did not open the full text of every one of the 35 references in this session (search step limit reached). Treat each mapping as a research lead, not a conclusion.
• Explicit uncertainty: I did not verify whether the USPTO prosecuted this application under pre‑AIA § 102 or the AIA § 102(a)(1)/(a)(2) framework. Because the family claims full 2006 priority, pre‑AIA is the more likely governing statute, but the file wrapper (Office actions of 2019‑06‑06 and 2019‑10‑02) would be needed to confirm which references were actually applied and under which subsection.

I'll ground the prior-art references cited on this patent's face before building the §103 analysis.

Let me ground the remaining reference families: the P&G strip patents, the Ultradent "solid/tray-like" device patents, and the water-soluble-polymer review the examiner cited.

Obviousness Analysis — U.S. Pat. No. 10,603,259 B2

"Peroxide Gel Compositions" (Cao Group, Inc.; inventor Steven D. Jensen)

35 U.S.C. § 103, using the prior art cited on the face of the patent

Scope note / ground rules. I am analyzing US 10,603,259 B2 literally and only as that number appears in the record. The prior art I rely on is the "Citations (27)," "Patent Citations (35)," and "Non-Patent Citations (9)" blocks on the Google Patents page for this patent (plus the "Similar Documents" only where I say so). I did not treat the "Family Cites Families" or "Families Citing this family" lists as prior art — they are citation topography, not references of record. Where I could not verify a reference's full text, I say so rather than reconstruct it.

0. Threshold issues that control the whole analysis

0.1 Effective filing date — and why it matters more here than usual. This patent issued from App. 15/488,293 (filed 2017-04-14), which the record shows is a continuation of US 14/710,416 (filed 2015-05-12, issued as US 9,789,036), itself a continuation of US 12/329,582 (filed 2008-12-06, issued as US 9,295,619), itself a CIP of US 11/307,463 (filed 2006-02-08, published as US 2007/0183987 A1). Priority is listed as 2006-02-08 and anticipated expiry as 2026-02-08.

Three candidate § 102 cutoff dates therefore exist:

Analytical consequence: the entire patent-citation block predates 2006-02-08, so for § 103 purposes it is prior art whether priority is 2006 or 2017. The date matters only for four NPL items: Gowda et al., Polymers 3:1972-2009 (2011), Kadajji et al., Polymers 3:1972-2009 (2011), Kim, "How to Make Korean Jello" (2017), and Velesco, "Science Behind Gels" (2017). The last two post-date even the 2017-04-14 filing and are flagged with † (cited by third party) on the page — they cannot be § 102 prior art against the '259 claims at any priority date, but they can be used as evidence of the knowledge and level of skill in the art at the relevant time, which is a permissible § 103 use. The 2011 reviews sit in the gap: prior art only if the claims' effective date is 2015+, which I consider unlikely given the 2008 CIP disclosure. I use them as background evidence, not as § 102 art.

0.2 A structural threshold point. Because the 2006, 2008, 2015, and 2017 filings all share a common specification lineage, the applicant's own earlier published family members (US 2007/0183987; US 2009/0238779) are not available as prior art against the '259 claims (common ownership / same inventive entity / continuation lineage). That removes what would otherwise be the single most on-point reference against these claims. An attacker must therefore build the case from third-party art.

1. The prior art of record, grouped by what it teaches

Group A — Flexible, water-insoluble backing strip + peroxide gel conformed to adjacent teeth (the device architecture)

The Sagel / Procter & Gamble strip family is the backbone of the device-side case:

• US 5,891,453 and US 5,894,017 (both 1997-06-06; issued 1999) — a strip of material with flexural stiffness < about 50 g/cm, "readily conformable without permanent deformation to a shape of a tooth and its adjoining soft tissue," carrying a tooth-whitening substance that "provides adhesive attachment between the strip and the surface," with the substance "in the form of a gel… a substantially uniform continuous coating." Figures 5–6 show it applied to "a plurality of adjacent teeth." Verified via the patent texts.
• US 6,045,811 — same architecture with a permanently deformable strip.
• US 6,136,297, US 6,582,708, US 6,884,426, US 7,122,199 and the P&G continuations US 2002/0006387, US 2007/0003495, US 2007/0253990, US 2007/0269471 — methods and delivery substances, including extrusion-resistance limitations ("not substantially extruded… during manual deformation of the strip"). Verified from the PTAB exhibit texts returned in search.
• US 6,514,483 (Colgate), US 6,685,923 (Dentsply), US 6,780,401 / US 7,862,802 (LG Household — "Patches for teeth whitening"), US 2004/0136927 (Kim), US 2005/0186150 (Allred — protective adhesive region), US 2005/0255054 (Philp — dissolvable tray or strip), US 2005/0276760 (Lornamead), US 6,322,360 and US 6,315,566 (3M).

Group B — Peroxide + polymeric thickener/complex chemistry

• ISP Technical Bulletin, "Hydrogen Peroxide–Polyvinylpyrrolidone Polymer Complexes" (2004) — the single most important NPL reference. It establishes that PVP is used with hydrogen peroxide as a thickening/binding polymer and as a peroxide complex, i.e., PVP was known to be peroxide-compatible.
• US 5,008,093 and US 5,190,749 (not of record on this patent but found via search) confirm the same class of art existed at least a decade before the priority date (PVP–H₂O₂ complexes, "free-flowing powder," 10–23 wt% H₂O₂, ≤5% water).
• US 2004/0241110 A1 (Sang-Ho Lee), "Jelly-type tooth-bleaching patch" — a film/backing with a jelly adhesive containing hydrogen peroxide, a PVP "coating-forming agent," ethanol, water, glycerin, and sweetener/flavor, wrapped with moisture-proof wrapping paper; the reference states the patch "is flexibly attached to teeth in accordance with the teeth shape" and prevents the bleaching agent from being diluted by saliva. Confirmed directly from the reference's own text and claims. Note especially that Lee's claim 1 recites [film] + [adhesive on the film] + [moisture-proof wrapping] — i.e., a packaged jelly-on-film whitening device.
• US 2004/0105834 A1 (Corium) — hydrogel compositions with an erodible backing member.
• US 2003/0073150 A1 (Woerner) — stabilization of H₂O₂.

Group C — Poly(2-ethyl-2-oxazoline) as a known water-soluble polymer

• Polymer Chemistry Innovations "AQUAZOL" MSDS (2002) — the record's own citation. PEOX, CAS 25805-17-8. Corroborated by product literature returned in search: AQUAZOL grades are 50,000 / 200,000 / 500,000 MW; "freely soluble in water" and soluble in polar organics including ethanol; thermoplastic, forms a good film, with "excellent film forming, strong adhesion and… tackiness properties"; and is described as "a preferred substitute for PVOH and PVP in high temperature applications."
• Aldrich Catalog 2005-2006 (cited by the examiner) — a commercial availability reference for the polymer.
• US 4,144,211 (Dow Chemical, 1979) — "Novel complexes of polyoxazolines or polyoxazines and halogens, interhalogens or pseudo-halogens." This reference is double-edged and important: it shows the art had already complexed polyoxazoline with strong oxidizing species 27 years before priority. An attacker cites it as a compatibility teaching; the patent owner would try to flip it into a teaching-away.
• US 5,470,930 (Nippon Shokubai) — polyoxazoline-related polymer chemistry.

Group D — "Solid / substantially solid / dried" composition on a backing (the dried-state architecture)

• US 6,860,736 (Ultradent) — oral treatment devices with a thin, flexible barrier layer and an "endoskeleton treatment or adhesive composition."
• US 7,056,118 (Ultradent) — "Compositions and devices having a tray-like configuration."
• US 7,059,857 (Ultradent) — "Substantially solid desensitizing compositions and devices having a tray-like configuration."
• US 6,730,316 (Ultradent) — dental bleach.
• Corroborating "similar document": EP 1,633,273 B1 ("thin, flexible barrier layer and an endoskeleton treatment").

Group E — Lactam/polymer stability chemistry

• Imming et al., "Hydrolytic Stability versus Ring Size in Lactams," J. Med. Chem. 43:4328–4331 (2000) — cited by the examiner. Both PEOX (N-acyl, 2-oxazoline repeat) and PVP (a lactam) are amide/lactam-containing polymers; this reference goes to the known hydrolytic behavior of the ring systems common to both polymers. It is the kind of reference an examiner uses to pre-empt a "the polymer is unexpectedly stable" argument by showing the relevant chemistry was understood.

2. Claim-construction points that drive the § 103 outcome

3. Combination I — Sagel (P&G strip) + ISP PVP–H₂O₂ bulletin + AQUAZOL/Aldrich (PEOX)

Base reference: US 5,891,453 (or US 6,045,811 as the "permanently deformable" variant).
Secondary references: ISP Technical Bulletin (2004); AQUAZOL MSDS (2002); Aldrich Catalog (2005-06).

Motivation to combine. The '259 specification itself frames the motivation: the field knew that "there are very few thickeners that can withstand a peroxide environment," that CARBOPOL "does not hold up to pure hydrogen peroxide," and that what was needed was a polymer "capable of withstanding hydrogen peroxide compositions for moderate amounts of time." A POSITA reading the ISP bulletin (PVP is thickener/binder and forms stable H₂O₂ complexes) and the AQUAZOL literature (PEOX is a water- and alcohol-soluble, film-forming, tacky substitute for PVP and PVOH) has an express, art-recognized reason to substitute those polymers into a known strip device to solve the art-recognized peroxide-degradation problem. The result — a flexible, adhesive, conformable peroxide layer on a flexible strip — is the predictable product of combining those teachings.

Weakness of this combination. It does not directly teach thickener dominance over water, and it does not demonstrate six-month stability at 30% H₂O₂. Both must be argued as optimization/inherency.

4. Combination II — Lee US 2004/0241110 (jelly whitening patch) + AQUAZOL/Aldrich (PEOX substitution)

This is the most structurally complete single reference in the record, and correspondingly the most dangerous.

Lee discloses, in one document:

• a backing film;
• a jelly adhesive containing hydrogen peroxide (or carbamide peroxide, sodium percarbonate, sodium perborate — claim 4);
• a polymeric "coating-forming agent" expressly including polyvinylpyrrolidone (claim 9 / [0019]);
• water and ethyl alcohol as co-solvents ([0044] Table 1: "Purified water (54.5), ethyl alcohol (4)");
• a sweetening/flavoring system;
• moisture-proof wrapping (claim 1) — i.e., packaging;
• and the express functional statement that the patch is "flexibly attached to teeth in accordance with the teeth shape" and holds the bleaching agent against the teeth "at a sufficient concentration for a sufficient time."

The only missing element for claim 1 is (a) PEOX as the thickener and (b) thickener > water by weight.

Motivation to combine (a): the AQUAZOL literature expressly positions PEOX as a substitute for polyvinylpyrrolidone (PVP), which Lee uses. "Substituting one known polymer for another to achieve the same or a similar function" is a recognized, KSR-sanctioned rationale (MPEP 2144.03; In re Fout; In re Crockett). PEOX and PVP are both water-soluble, non-ionic, film-forming, hydrogen-bonding polymers with documented use as thickeners — closely analogous. A POSITA seeking greater viscosity at lower solids loading, better film flexibility, or better thermal/oxidative processing latitude would reach for PEOX precisely because the art says it substitutes for PVP.

Motivation to combine (b): claim 1's thickener-dominance is a weight ratio. Lee's own examples include formulations in which PVP is a minority ingredient, but Lee's own teaching that the jelly must be cohesive enough to be "flexibly attached" supplies the direction — increase the polymer and reduce water until the jelly holds together on the film. In re Aller makes that optimization obvious in the absence of criticality.

Counter to the "PVP is only a coating-forming agent, not a thickener" objection: Lee's own claim language distinguishes "coating-forming agent" from "coating-forming aid" (hydroxypropyl cellulose, methyl cellulose, etc.), and PVP is grouped with the structure-building polymers. A POSITA would understand PVP there as the film/thickener component. Verified against Lee's text.

Dependency chain. Claims 4/6/18/20 (organic solvent = ethanol/PEG/PPG/glycerin/propylene glycol) are met by Lee's ethanol + glycerin + "polyoxyethylene glycol." Claims 5/19/28 (more water than organic solvent) are met by Lee's Table 1. Claims 11/25 (thickener 33–50 wt%) and 12/26 (peroxide 11–27 wt%) are numerical ranges — reachable by routine optimization once the base combination is established. Claim 9/23 (PVP) is met directly by Lee without any substitution.

5. Combination III — Ultradent solid/tray-like devices (US 7,059,857 / 6,860,736 / 7,056,118) + PEOX (AQUAZOL/Aldrich)

Base: Ultradent's "substantially solid" and "tray-like configuration" compositions on a thin, flexible barrier layer.
Secondary: AQUAZOL MSDS/Aldrich; ISP bulletin.

Why this combination attacks the claim's hardest limitation. The '259 specification concedes the state of the art: "Other disclosed inventions include more rigid or solidified treatment compositions that are set into a tray or onto a backing material… they do resist flow… However, they do crack and break if flexed." That sentence is, in effect, a statement of the problem whose solution the claim purports to be. An attacker uses Ultradent for every structural element (dried/solid composition + flexible backing + conformable to the dental arch) and uses the AQUAZOL literature for the single asserted point of novelty (PEOX is a film-forming, flexible, water-soluble polymer with "strong adhesion and tackiness," positioned as a PVP/PVOH substitute). The motivation is squarely in the art: the field wanted a solidified, non-running composition that would not crack when the device was flexed. PEOX's documented film formation and elasticity supply the predictable answer.

Note the anti-obviousness asymmetry. The '259 specification's own recitation of the "ideal thickener" characteristics — adhesion in an aqueous environment, hygroscopicity, organic-solvent compatibility, elasticity without cracking — reads like a product specification for PEOX as it was already described commercially (water- and ethanol-soluble, film-forming/tacky, hygroscopic-adjacent). That is a strong indicator that the selection of PEOX was the predictable identification of a known material meeting a known set of requirements, not an act of invention.

6. Combination IV — High-peroxide in-office gels + PVP–H₂O₂ complex art + strip hardware (attacking claims 12, 13, 26)

For the concentration ranges (11–27 wt%, and up to ~50 wt%), the art supplies:

• in-office 30–35% hydrogen peroxide whitening gels are described as background in Sagel US 5,891,453 ("typically hydrogen peroxide" at strengths requiring a rubber dam) and in the '259 specification itself;
• US 5,008,093 / US 5,190,749 and the ISP bulletin show PVP–H₂O₂ complexes at 13–23 wt% H₂O₂ with ≤5% water — i.e., thickener-dominant by weight — and the contemporaneous commercial complex (Peroxydone-type) is described at ~15–18% H₂O₂.
• US 6,514,483 (Colgate strip for whitening tooth surfaces) and US 2002/0155070 / US 6,500,408 (Chen, "enamel-safe tooth bleach") supply the strip-plus-bleach combination.

Together these show that thickener-dominant peroxide compositions were a known design space, which undercuts the "more thickener than water" and "more thickener than peroxide" limitations as inventive differentiators.

7. Motivation-to-combine rationales, mapped to the KSR/MPEP categories

8. Dependent claims

9. Where the obviousness case is weak, and the patent owner's best rebuttals

9.1 The strongest non-obviousness argument — thickener dominance plus gel-state after drying. None of the four combinations directly discloses a dried, still-gelatinous, polymer-dominant peroxide layer on a flexible strip that survives six months packaged. The patent owner will argue that:

• the art's gels were water-dominant and wet (P&G, Colgate, Lee);
• the art's dried compositions were brittle solids (Ultradent), which the specification expressly criticizes;
• the claimed combination — dried and gelatinous and flexible and stable — was not suggested; and
• the claimed weight ratios (33–50% thickener) are alleged to be critical to that combination.

Assessment: this is a real argument but a fragile one. It rests on the patent's own characterizations of the art (which are admissions), not on comparative data. The specification contains no side-by-side comparison of PEOX against PVP, Carbopol, or silica under identical conditions — the only quantified statement is that "a 30% hydrogen peroxide gel made with Poly(2-ethyl-2-oxazoline) stays a gel during six month's storage." Under In re Geisler / MPEP 716.02, an unexpected-results rebuttal requires the results to be unexpected relative to the closest prior art, and a bare assertion without comparative evidence generally fails. Expect an obviousness holding to survive this rebuttal.

9.2 Possible teaching away. The AQUAZOL-type SDS language "Do not store together with: strong oxidants" (appearing in later, modern SDS versions — the 2002 MSDS of record would need to be checked for the identical phrase before this can be relied on) could be argued as a teaching away from putting PEOX with hydrogen peroxide. Two responses: (i) the same document class also shows PEOX as a PVP substitute, and PVP was already used with peroxide, so a POSITA would not treat the caution as a categorical teaching away; and (ii) US 4,144,211 (Dow) teaches polyoxazoline–halogen/interhalogen/pseudo-halogen complexes — strongly oxidizing species — which cuts against any teaching-away theory.

9.3 Secondary considerations available to the patent owner.

• Long-felt need / failure of others: the specification's account of CARBOPOL's failure at 30% H₂O₂ is the classic failure-of-others narrative. Weight is limited because PVP–H₂O₂ complexes were already commercially available, so the need was at least partly met.
• Commercial success: the patent's litigation history (multiple actions naming the '259 patent, including the Ranir LLC v. CAO Group declaratory-judgment action and multiple Schedule A filings) indicates a commercially significant product, but no evidence of nexus to the claimed weight ratios appears in the record.
• Copying: the accused third-party whitening strips could support a copying narrative, but again requires nexus.
• Praise / industry acceptance: not evidenced.

9.4 Inherency risk for the patent owner. If an attacker produces evidence that a prior-art PVP–H₂O₂ complex or PEOX-thickened H₂O₂ gel inherently remains gelatinous for six months at room temperature, the stability limitation is neutralized and the case collapses to the weight ratios — a pure optimization issue.

10. Conclusion

Claims 1, 14, and 27 are, in my assessment, vulnerable to a § 103 obviousness challenge, and the most probable outcome of a well-litigated validity challenge is that the broadest claims would be invalidated or substantially narrowed.

• Claim 1 is met or near-met by US 2004/0241110 (Lee) combined with AQUAZOL/Aldrich (PEOX) and the ISP PVP–H₂O₂ bulletin; the residual gap is the thickener-dominance ratio, which is optimization.
• Claim 14 adds an organic-solvent recitation (Lee: ethanol/glycerin/polyoxyethylene glycol) and a three-way weight comparison — same result.
• Claim 27 adds nothing but a relative-weight ranking and an "ethyl alcohol" designation (also met by Lee) plus the antecedent inconsistency noted above.
• The P&G Sagel strip family + PEOX/PVP art provides a second, independent route covering the device architecture and the conformability/adhesion limitations.
• Ultradent's solid/tray-like references + PEOX art provides a third route that specifically targets the "dried yet flexible/gelatinous" requirement.

Most defensible claim: claim 1 (or its dependents) only if the patent owner can show criticality of the 33–50 wt% thickener loading with real comparative data — which the specification does not currently supply.

11. Confidence, and what I could not verify

High confidence (verified against reference text in this session): Lee US 2004/0241110A1's composition and claim set; P&G US 5,891,453 / US 5,894,017 / the low-flexural-stiffness family's disclosure of conformable strip + peroxide gel + adjacent-teeth application + extrusion resistance; the AQUAZOL/PEOX identity (CAS 25805-17-8), MW grades (50k/200k/500k), water and ethanol solubility, and film-forming/tack/adhesion properties; the ISP/NPL basis for peroxide–PVP complexes; the '259 claim text and specification.

Moderate confidence: the precise scope of Ultradent US 6,860,736 / 7,056,118 / 7,059,857 — I relied on the titles, abstracts, and the '259 specification's own characterization, and on the "Similar Documents" listing, not on a full-text read.

Could not verify (explicitly flagged, no fabrication):

1. The 2002 AQUAZOL MSDS of record itself — I confirmed the substance identity and properties from a later AQUAZOL SDS and from PCI/Aldrich product literature indexed by search, but not the 2002 document's exact wording, so the "do not store with strong oxidants" teaching-away argument (§ 9.2) needs the 2002 document checked before it can be asserted.
2. The full text of Imming et al. (2000) and of the Gowda/Kadajji 2011 reviews — I know they are lactam-stability and water-soluble-polymer reviews, respectively (verified as to title/venue in the record), but I did not read them, so I have not quoted them and I do not rely on them as primary prior art.
3. The three "Similar Documents" and the "Families Citing this family" entries (e.g., WO 2015/053808, US 2023/0210731) are not prior art of record for this patent and I did not use them; US 11,826,444 / 11,826,445 are later family members, and the '259 patent's own record shows the family continuing to issue through 2023, which is consistent with ongoing prosecution difficulty but is not itself a validity fact.

One contradiction to flag with the previously generated sections: the earlier litigation section cites N.D. Ill. 1:25-cv-04054 with unverified venue and lists a case it numbers 25-cv-14512, whereas the patent's own Google Patents page lists the 2025 N.D. Ill. Schedule A matter as 1:25-cv-04054 and does not show a 14512 entry. I cannot resolve that from the material available to me and I have not treated either docket as a validity-relevant fact.

Requested-but-unrun searches: I was unable to complete searches on the Ultradent references' full specifications and on any pre-2006 art that expressly teaches thickener-dominant (>50 wt% polymer) peroxide gels, which is the single most useful additional evidence an attacker could obtain.